Earnings Report /

Square Pharmaceuticals: Annual FY21 – c19% yoy earnings growth meets our expectation

  • EPS of the company stood at BDT 18.0 (NPAT BDT 15,940mn) in FY21, implying c19% growth

  • SQUARE declared BDT 6.0/share cash dividend (c33% pay-out) in FY21

  • We reiterate Buy for SQUARE with TP of BDT 275.0 (ETR 20.2%).

Tanay Kumar Roy
Tanay Kumar Roy

Research Analyst

Shopnil Paul
Shopnil Paul

Research Associate

IDLC Securities
24 October 2021
Published by